Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

I. Cheng Lee; Yi Hsiang Huang; Chi Jen Chu; Pui Ching Lee; Han Chieh Lin; Shou Dong Lee

doi:10.1016/S1726-4901(10)70031-9

Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

I. Cheng Lee, Yi Hsiang Huang^*, Chi Jen Chu, Pui Ching Lee, Han Chieh Lin, Shou Dong Lee

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

A 72-year-old female negative for hepatitis B surface antigen (HBsAg) and positive for antibody to hepatitis B surface antigen (anti-HBs) was diagnosed to have follicular lymphoma in 2006. Seventeen cycles of rituximab-based chemotherapy were administered over 23 months. Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and hepatitis serology tests revealed reappearance of HBsAg and hepatitis B e antigen (HBeAg), loss of anti-HBs, and positivity for hepatitis B virus (HBV) DNA. Antiviral treatment with entecavir was administered immediately, and the hepatitis flare was controlled. Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients. Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy.

Original language	English
Pages (from-to)	156-160
Number of pages	5
Journal	Journal of the Chinese Medical Association
Volume	73
Issue number	3
DOIs	https://doi.org/10.1016/S1726-4901(10)70031-9
State	Published - Mar 2010

Keywords

HBV reactivation
anti-HBc positive
chemotherapy
non-Hodgkin's lymphoma
rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1726-4901(10)70031-9

Cite this

@article{1f4a569d5e0f4707a20e4d41813cbe04,

title = "Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma",

abstract = "A 72-year-old female negative for hepatitis B surface antigen (HBsAg) and positive for antibody to hepatitis B surface antigen (anti-HBs) was diagnosed to have follicular lymphoma in 2006. Seventeen cycles of rituximab-based chemotherapy were administered over 23 months. Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and hepatitis serology tests revealed reappearance of HBsAg and hepatitis B e antigen (HBeAg), loss of anti-HBs, and positivity for hepatitis B virus (HBV) DNA. Antiviral treatment with entecavir was administered immediately, and the hepatitis flare was controlled. Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients. Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy.",

keywords = "HBV reactivation, anti-HBc positive, chemotherapy, non-Hodgkin's lymphoma, rituximab",

author = "Lee, {I. Cheng} and Huang, {Yi Hsiang} and Chu, {Chi Jen} and Lee, {Pui Ching} and Lin, {Han Chieh} and Lee, {Shou Dong}",

year = "2010",

month = mar,

doi = "10.1016/S1726-4901(10)70031-9",

language = "English",

volume = "73",

pages = "156--160",

journal = "Journal of the Chinese Medical Association",

issn = "1726-4901",

publisher = "Elsevier Taiwan LLC",

number = "3",

}

TY - JOUR

T1 - Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

AU - Lee, I. Cheng

AU - Huang, Yi Hsiang

AU - Chu, Chi Jen

AU - Lee, Pui Ching

AU - Lin, Han Chieh

AU - Lee, Shou Dong

PY - 2010/3

Y1 - 2010/3

N2 - A 72-year-old female negative for hepatitis B surface antigen (HBsAg) and positive for antibody to hepatitis B surface antigen (anti-HBs) was diagnosed to have follicular lymphoma in 2006. Seventeen cycles of rituximab-based chemotherapy were administered over 23 months. Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and hepatitis serology tests revealed reappearance of HBsAg and hepatitis B e antigen (HBeAg), loss of anti-HBs, and positivity for hepatitis B virus (HBV) DNA. Antiviral treatment with entecavir was administered immediately, and the hepatitis flare was controlled. Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients. Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy.

AB - A 72-year-old female negative for hepatitis B surface antigen (HBsAg) and positive for antibody to hepatitis B surface antigen (anti-HBs) was diagnosed to have follicular lymphoma in 2006. Seventeen cycles of rituximab-based chemotherapy were administered over 23 months. Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and hepatitis serology tests revealed reappearance of HBsAg and hepatitis B e antigen (HBeAg), loss of anti-HBs, and positivity for hepatitis B virus (HBV) DNA. Antiviral treatment with entecavir was administered immediately, and the hepatitis flare was controlled. Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients. Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy.

KW - HBV reactivation

KW - anti-HBc positive

KW - chemotherapy

KW - non-Hodgkin's lymphoma

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=77951007337&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(10)70031-9

DO - 10.1016/S1726-4901(10)70031-9

M3 - Article

C2 - 20231001

AN - SCOPUS:77951007337

SN - 1726-4901

VL - 73

SP - 156

EP - 160

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

IS - 3

ER -

Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this